Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

AI/ML

Biotechnology

Health Care

Pharmaceutical

Iktos

The Paris office focuses on business development, scientific research, and advanced technology solutions in the EU market.

Paris

The Tokyo office focuses on business development and operations, bridging local initiatives with global strategies.

People (1)

Jobs (0)

Other offices